|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-1.92/-2.67
|
企业价值
222.55M
|
资产负债 |
每股账面净值
1.47
|
现金流量 |
现金流量率
--
|
损益表 |
收益
155.00K
|
每股收益
0.01
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/21 15:18 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others. |